Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (II)
作者:Chunwei Cheng、Yan Liu、Hao Song、Lili Pan、Jerry Li、Yong Qin、Rongshi Li
DOI:10.3390/md11082927
日期:——
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major problem, causing severe and intractable infections worldwide. MRSA is resistant to all beta-lactam antibiotics, and alternative treatments are limited. A very limited number of new antibiotics have been discovered over the last half-century, novel agents for the treatment of MRSA infections are urgently needed. Marinopyrrole A was reported to show antibiotic activity against MRSA in 2008. After we reported the first total synthesis of (±)-marinopyrrole A, we designed and synthesized a series of marinopyrrole derivatives. Our structure activity relationship (SAR) studies of these novel derivatives against a panel of Gram-positive pathogens in antibacterial assays have revealed that a para-trifluoromethyl analog (33) of marinopyrrole A is ≥63-, 8-, and 4-fold more potent than vancomycin against methicillin-resistant Staphylococcus epidermidis (MRSE), methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA, respectively. The results provide valuable information in the search for new-generation antibiotics.
耐甲氧西林金黄色葡萄球菌(MRSA)仍然是一个大问题,在全球范围内造成严重和难以治愈的感染。MRSA 对所有β-内酰胺类抗生素都有耐药性,替代治疗方法有限。过去半个世纪中发现的新抗生素数量非常有限,因此迫切需要治疗 MRSA 感染的新型药物。2008 年,有报道称 Marinopyrrole A 对 MRSA 具有抗生素活性。在我们首次报道了 (±)-arinopyrrole A 的全合成之后,我们设计并合成了一系列 marinopyrrole 衍生物。我们对这些新型衍生物进行了结构活性关系(SAR)研究,发现它们在抗菌试验中对一组革兰氏阳性病原体的作用分别比万古霉素对耐甲氧西林表皮葡萄球菌(MRSE)、甲氧西林易感金黄色葡萄球菌(MSSA)和 MRSA 的作用强≥63 倍、8 倍和 4 倍。这些结果为寻找新一代抗生素提供了有价值的信息。